Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Express Scripts
Dow
Baxter
Mallinckrodt

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,738,643

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,738,643
Title:Substituted indazoles for targeting Hsp90
Abstract: Described herein are substituted indazoles that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. The compounds may include detection moieties such as fluorophores that may allow for selective detection of Hsp90 in a sample. Suitable compounds include those of formula (II): ##STR00001##
Inventor(s): Haystead; Timothy (Chapel Hill, NC), Hughes; Philip Floyd (Chapel Hill, NC)
Assignee: Duke University (Durham, NC)
Application Number:14/419,965
Patent Claims:1. A compound of formula (I): A-X.sup.1-L-X.sup.2--B (I) wherein: A is a heat shock protein 90 binding component; X.sup.1 is selected from the group consisting of --NH--, --O--, --S--, --C(O)-- and --S(O).sub.2--; X.sup.2 is selected from the group consisting of --NR--, --O--, --S--, --C(O)-- and --S(O).sub.2--; L is a divalent linker of the following formula: --(CH.sub.2).sub.m--(OCH.sub.2CH.sub.2).sub.n--O--(CH.sub.2).su- b.p-- wherein: m is 2 or 3; n is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; and p is 2 or 3; B is selected from the group consisting of a detection moiety, an anti-cancer agent, and a heat shock protein 90 binding component; and R is selected from the group consisting of --H and a detection moiety; wherein each heat shock protein 90 binding component independently has the following formula (II): ##STR00048## wherein: R.sup.1 and R.sup.2 are independently selected from the group consisting of --H and --C.sub.1-8-alkyl; Y is CR.sup.3 or N; R.sup.3 is --H, --F or --OCH.sub.3; R.sup.4 and R.sup.5 are independently selected from the group consisting of --H, --F and --OCH.sub.3; R.sup.6 is --C.sub.1-8-alkyl, --C.sub.2-8-alkenyl, --C.sub.2-8-alkynyl, --C.sub.3-8-cycloalkenyl, --C.sub.3-8-cycloalkenyl-C.sub.1-8-alkyl, --C.sub.3-8-cycloalkyl, --C.sub.3-8-cycloalkyl-C.sub.1-8-alkyl, aryl, aryl-C.sub.1-8-alkyl, halo-C.sub.1-8-alkyl, heteroaryl, heteroaryl-C.sub.1-8-alkyl, heterocyclyl, heterocyclyl-C.sub.1-8-alkyl, or hydroxy-C.sub.1-8-alkyl; R.sup.7 and R.sup.8 are independently selected from the group consisting of --H and --C.sub.1-8-alkyl; X is N; and ##STR00049## represents the point of attachment in formula (I); wherein each detection moiety independently comprises a fluorophore or a radioactive compound; wherein the fluorophore is a fluorescein, a rhodamine, a coumarin, a cyanine, or a boron-dipyrromethene; wherein the radioactive compound is a radioisotope; and wherein the anti-cancer agent is an alkylating agent, an anti-epidermal growth factor receptor antibody, an anti-Her-2 antibody, an antimetabolite, a vinca alkaloid, an anthracycline, a platinum-based agent, a topoisomerase inhibitor, a taxane, an anti-cancer antibiotic, an immune cell antibody, an interferon, an interleukin, a heat shock protein 90 inhibitor, an anti-androgen, an anti-estrogen, an antihypercalcemia agent, an apoptosis inducer, an aurora kinase inhibitor, a Bruton's tyrosine kinase inhibitor, a calcineurin inhibitor, a Ca.sup.2+-calmodulin-dependent protein kinase II inhibitor, a CD45 tyrosine phosphatase inhibitor, a cell division cycle 25 phosphatase inhibitor, a checkpoint kinase inhibitor, a cyclooxygenase inhibitor, a cRAF kinase inhibitor, a cyclin dependent kinase inhibitor, a cysteine protease inhibitor, a deoxyribonucleic acid intercalator, a deoxyribonucleic acid strand breaker, an E3 ligase inhibitor, an epidermal growth factor pathway inhibitor, a farnesyltransferase inhibitor, a fetal liver kinase-1 inhibitor, a glycogen synthase kinase-3 inhibitor, a histone deacetylase inhibitor, an I-kappa B-alpha kinase inhibitor, an imidazotetrazinone, an insulin tyrosine kinase inhibitor, a c-Jun N-terminal kinase inhibitor, a mitogen-activated protein kinase inhibitor, a mouse double minute 2 inhibitor, an MEK inhibitor, a matrix metalloproteinase inhibitor, a mammalian target of rapamycin inhibitor, a nerve growth factor receptor tyrosine kinase inhibitor, a p38 mitogen-activated protein kinase inhibitor, a p56 tyrosine kinase inhibitor, a platelet-derived growth factor pathway inhibitor, a phosphatidylinositol 3-kinase inhibitor, a phosphatase inhibitor, a protein phosphatase inhibitor, a protein kinase C inhibitor, a protein kinase C delta kinase inhibitor, a polyamine synthesis inhibitor, a protein tyrosine phosphatase 1B inhibitor, a protein tyrosine kinase inhibitor, an SRC family tyrosine kinase inhibitor, a spleen tyrosine kinase inhibitor, a Janus tyrosine kinase inhibitor, a retinoid, a ribonucleic acid polymerase II elongation inhibitor, a serine/threonine kinase inhibitor, a sterol biosynthesis inhibitor, a vascular endothelial growth factor pathway inhibitor, alitretinon, altretamine, aminopterin, aminolevulinic acid, amsacrine, asparaginase, atrasentan, bexarotene, carboquone, demecolcine, efaproxiral, elsamitrucin, etoglucid, a Gliadel implant, hydroxycarbamide, leucovorin, lonidamine, lucanthone, masoprocol, methyl aminolevulinate, mitoguazone, mitotane, oblimersen, omacetaxine, pegaspargase, porfimer sodium, prednimustine, sitimagene ceradenovec, talaporfin, temoporfin, trabectedin or verteporfin.

2. The compound of claim 1, wherein A has the formula: ##STR00050##

3. The compound of claim 1, wherein B is a detection moiety.

4. The compound of claim 3, wherein B is a fluorophore.

5. The compound of claim 1, wherein B is an anti-cancer agent.

6. The compound of claim 1, wherein B is a heat shock protein 90 binding component.

7. The compound of claim 1, wherein: R.sup.1 and R.sup.2 are independently --H; Y is CR.sup.3; R.sup.3 is --H; R.sup.4 and R.sup.5 are independently --H; R.sup.6 is --C.sub.1-8-alkyl or halo-C.sub.1-8-alkyl; and R.sup.7 and R.sup.8 are independently --C.sub.1-8-alkyl.

8. The compound of claim 1, wherein m is 3 and p is 3.

9. The compound of claim 1, wherein n is 4.

10. A kit comprising a compound of claim 1.

Details for Patent 9,738,643

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 1978-01-10 ⤷  Free Forever Trial 2032-08-06
Servier Pharmaceuticals Llc ONCASPAR pegaspargase Injection 103411 1994-02-01 ⤷  Free Forever Trial 2032-08-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Colorcon
Express Scripts
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.